Astellas and Seattle Genetics are preparing to file for FDA approval of enfortumab on the strength of phase 2 data. The trial linked the antibody-drug conjugate to a 44% response rate in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results